Investment Analysts’ Recent Ratings Changes for Passage Bio (PASG)

Several brokerages have updated their recommendations and price targets on shares of Passage Bio (NASDAQ: PASG) in the last few weeks:

• 5/3/2026 – Passage Bio was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 4/25/2026 – Passage Bio was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 4/21/2026 – Passage Bio was given a new $7.00 price target by Chardan Capital. They now have a “neutral” rating on the stock.
• 4/21/2026 – Passage Bio was downgraded by Chardan Capital from “buy” to “hold”. They now have a $7.00 price target on the stock, down from $21.00.
• 4/21/2026 – Passage Bio had its price target lowered by Oppenheimer Holdings, Inc. from $30.00 to $15.00. They now have an “outperform” rating on the stock.
• 4/21/2026 – Passage Bio was downgraded by TD Cowen from “buy” to “hold”.
• 4/21/2026 – Passage Bio had its “neutral” rating reaffirmed by Wedbush. They now have a $8.00 price target on the stock, down from $32.00.
• 4/20/2026 – Passage Bio is now covered by Wedbush. They set a “reduce” rating on the stock.
• 4/20/2026 – Passage Bio was downgraded by Lucid Cap Mkts from “strong-buy” to “hold”.
• 3/31/2026 – Passage Bio is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $30.00 price target on the stock.
• 3/27/2026 – Passage Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/7/2026 – Passage Bio was downgraded by Wall Street Zen from “hold” to “sell”.

Passage Bio is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. The company applies its in-house gene therapy platform to design and engineer adeno-associated virus (AAV)–based vectors that restore or replace defective genes, aiming to deliver durable treatments with a single administration.

The company’s lead programs include PBGM01, an AAV9-based therapy for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is conducting a first-in-human study to assess safety and potential therapeutic benefit.